CD68 and cryopyrin-associated periodic syndrome: Thus, the validated 18 hub genes, namely ITGB7, PTPN11, JAM3, ITGA8, IL10, ITGAL, ITGA4, ITGA9, CD4, CD1C, PTPRC, CD163, TNF, BTK, CD68, MRC1, LYN, and CD80, were selected, and these genes were found to have the ability to differentiate between the CAPs and control groups.